The advent of small-molecule targeted therapies, a decade ago, revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite a remarkable ...
Sep 22, 2022
0
31
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of ...
Sep 13, 2022
0
20
In the war against cancer, one of the most critical battles is waged on a cellular level as T cells from the immune system are altered in the lab to attack cancer cells. This form of immunotherapy, called chimeric antigen ...
Aug 25, 2022
0
69
The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type, according to results from the international ...
Aug 12, 2022
0
36
An international group of researchers investigated why mutations often associated with renal cancer result specifically in renal cancer, instead of other cancer types.
Aug 9, 2022
0
85
Hormone therapy is successful at keeping metastatic prostate cancer under control, but eventually the tumor cells become resistant to it. An unexpected potential solution has now emerged in medicines not designed to fight ...
Jun 27, 2022
0
79
Results of a study of molecular tumor profiling in young patients revealed a high rate of genetic alterations with potential for impacting clinical care, including clarifying diagnoses and treatment with matched, precision ...
Jun 23, 2022
0
49
Scientists have identified a new treatment combination that is highly effective at suppressing the growth of head and neck tumors.
Jun 16, 2022
0
5
More than 81,000 new cases of bladder cancer will be diagnosed in the U.S. in 2022, and more than 17,000 people will die of the disease, according to the American Cancer Society.
Jun 1, 2022
0
2
For patients with sentinel lymph node (SLN)-positive melanoma, fewer patients are undergoing completion lymph node dissection (CLND) and more are receiving adjuvant systemic therapy, according to study published online Jan. ...
Mar 9, 2022
0
2
